NCT03878524: A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Chemotherapy, Endocrine (Hormone Therapy, Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor, Immunotherapy, Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 21 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Participants with HR+ and/or HER2+ disease must have failed all prior therapies considered to be standard of care
Exclusions: Participants with uncontrolled metastases to the CNS and/or were diagnosed within the past 4 weeks of screening; Patients with unusual breast cancer subtypes; Patients with 3+ chemotherapy treatments with compromised organ function- see trial for details

Comments are closed.

Up ↑